SANNA, ALESSANDRO
 Distribuzione geografica
Continente #
EU - Europa 103
AS - Asia 89
NA - Nord America 86
SA - Sud America 15
AF - Africa 8
Totale 301
Nazione #
US - Stati Uniti d'America 82
RU - Federazione Russa 63
SG - Singapore 45
IT - Italia 19
CN - Cina 14
BR - Brasile 13
VN - Vietnam 13
HK - Hong Kong 10
GB - Regno Unito 7
DE - Germania 4
FR - Francia 4
BJ - Benin 3
MX - Messico 3
NG - Nigeria 3
KR - Corea 2
PL - Polonia 2
AE - Emirati Arabi Uniti 1
BD - Bangladesh 1
BE - Belgio 1
CA - Canada 1
CG - Congo 1
CO - Colombia 1
ES - Italia 1
IN - India 1
MT - Malta 1
NP - Nepal 1
PK - Pakistan 1
PY - Paraguay 1
SE - Svezia 1
TG - Togo 1
Totale 301
Città #
Singapore 26
San Jose 21
Ashburn 20
Moscow 17
Dallas 11
Hong Kong 10
Verona 9
Beijing 6
Ho Chi Minh City 5
Los Angeles 4
Tianjin 4
Cotonou 3
Hanoi 3
Padua 3
Abuja 2
London 2
Redondo Beach 2
San Francisco 2
São Paulo 2
Warsaw 2
Araguaína 1
Asunción 1
Belfast 1
Biên Hòa 1
Bogotá 1
Brazzaville 1
Brussels 1
Bắc Giang 1
Castelfranco Veneto 1
Centro Municipality 1
Chennai 1
Ciserano 1
City of London 1
Comitán 1
Council Bluffs 1
Da Nang 1
Denver 1
Dhaka 1
Espera Feliz 1
Frankfurt am Main 1
Guanambi 1
Houston 1
Joanópolis 1
Kathmandu 1
Lagos 1
Lomé 1
Luziânia 1
Madrid 1
Mexico City 1
Montes Claros 1
Montreal 1
Msida 1
Munich 1
New York 1
North Bergen 1
Offenbach 1
Orem 1
Paraisópolis 1
Paris 1
Penápolis 1
Phoenix 1
Plano 1
Poplar 1
Raleigh 1
Rawalpindi 1
Rio Claro 1
Santa Clara 1
Seattle 1
São Leopoldo 1
São Luís 1
Sóc Trăng 1
Turin 1
Totale 206
Nome #
Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study 127
Venetoclax based regimens in octogenarian CLL patients: efficacy, safety and comparison to BTKi in a multicenter cohort 89
How COVID-19 pandemic changed our attitude to venetoclax-based treatment in chronic lymphocytic leukemia 76
Real‐life efficacy and safety of vemurafenib plus rituximab in relapsed or refractory hairy‐cell leukemia: A multicenter Italian retrospective study (HCL‐PG03R) 4
Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real-World Study 4
Rethinking the feasibility and safety of venetoclaxobinutuzumab in chronic lymphocytic leukemia: nontraditional factors may play a role in clinical practice 4
Real-world safety and effectiveness of zanubrutinib vs ibrutinib in CLL: the CLL-ZANU2024 Italian cohort 4
Totale 308
Categoria #
all - tutte 1.179
article - articoli 1.179
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.358


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2022/20235 0 0 0 0 0 0 2 1 0 1 1 0
2023/20249 1 1 1 0 1 2 1 1 0 0 0 1
2024/202548 1 1 1 5 1 1 0 0 10 2 9 17
2025/2026246 13 11 15 40 65 14 18 23 12 12 14 9
Totale 308